The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Based Chemotherapy Drugs

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03048591

Enrollment

Registered

2017-02-09

Start date

2018-02-10

Completion date

2018-11-01

Last updated

2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced Peripheral Neuropathy

Brief summary

Through the research to confirm the effectiveness and safety of using electroacupuncture in the treatment of chemotherapy-induced peripheral neuropathy.

Interventions

DEVICEelectroacupuncture

Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. The histopathological and / or cellular pathology results prove malignancy of the tumor and the patient has received chemotherapy treatment before. 2. 15weeks after the completion of chemotherapy, the limbs are still feeling abnormal and the symptoms fulfill World Health Organization (WHO) grade 2 or more. 3. zubrod - Eastern Cooperative Oncology Group-WHO (ZPS) grade 0-2, cardiac function, liver function and renal function are not significantly abnormal, the survival period of the patient is expected to be more than 6 months. 4. Gender unrestricted, aged between 18 to 80 years old. 5. Voluntary participation in the study, will to sign informed consent, willing to comply with randomized grouping, will to follow-up.

Exclusion criteria

1. Patients who suffer from peripheral neuropathy due to infection, radiotherapy, HIV, chronic alcoholism, hypothyroidism, diabetes, paraneoplastic syndrome or other diseases; or are suffering from nervous system diseases. 2. Patients who are being treated with other drugs that may lead to neurotoxicity . 3. Patients with blood coagulation disorder. 4. Pregnancy and lactating women. 5. Patients with infection, scarring or defects near the acupoint sites. 6. Received intervention for the prevention and treatment of peripheral neuropathy 2 weeks before screening or has received traditional Chinese medicine (acupuncture, moxibustion, cupping, Chinese medicine therapy one month before.

Design outcomes

Primary

Measure	Time frame
Quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy (QLQ-CIPN20)	6 weeks

Secondary

Measure	Time frame
Functional Assessment of Cancer Treatment - General scale（FACT-G）	6 weeks

Contacts

Primary ContactBin Wang

wbin8888@163.com+8613820156627

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026